You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

isocitrate dehydrogenase (IDH) wild-type

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Brain Tumor, Cancer Trial run by the National Cancer Institute (NCI) (Zotiraciclib)

Not yet recruiting
  • Brain Tumor
  • Cancer
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia

Recruiting
  • Acute Myeloid Leukemia
  • +6 more
  • Biospecimen Collection
  • +2 more
  • Orange, California
  • +9 more
Jan 27, 2023

Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype Trial in Calgary (Niacin CRT)

Recruiting
  • Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
  • Niacin CRT
  • Calgary, Alberta, Canada
    Tom Baker Cancer Centre
Jul 18, 2022

Glioma, Malignant, Computer-Assisted Trial in Shanghai (Validation of IDH1 mutations from the radiomics model)

Active, not recruiting
  • Glioma, Malignant
  • Computer-Assisted
  • Validation of IDH1 mutations from the radiomics model
  • Shanghai, Shanghai, China
    Huashan Hospital, Fudan University
Jul 23, 2023

Glioma of Brain Trial in Bern, Lausanne, Zürich (L19TNF)

Active, not recruiting
  • Glioma of Brain
  • Bern, Switzerland
  • +2 more
Apr 7, 2022

Glioblastoma, IDH-wildtype, MGMT-Methylated Glioblastoma Trial in Padova (Regorafenib, Temozolomide)

Recruiting
  • Glioblastoma, IDH-wildtype
  • MGMT-Methylated Glioblastoma
  • Padova, Italy
    Istituto Oncologico Veneto IRCCS
Oct 18, 2023

Epilepsy; Seizure Trial (ES-481)

Withdrawn
  • Epilepsy; Seizure
  • (no location specified)
Mar 28, 2022

Vascular Habitats Within Astrocytoma Grade 4 at Molecular,

Recruiting
  • Astrocytoma, Grade IV
  • +7 more
    • Valencia, Spain
      Biomedical Data Science Lab. Universitat Politècnica de València
    May 11, 2022

    Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme Trial in Cleveland (Eflornithine (Dose Level 1), Eflornithine

    Recruiting
    • Glioblastoma, IDH-wildtype
    • +4 more
    • Eflornithine (Dose Level 1)
    • +3 more
    • Cleveland, Ohio
      The Cleveland Clinic
    May 19, 2023

    Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma Trial (Biospecimen Collection,

    Not yet recruiting
    • Recurrent Glioblastoma, IDH-Wildtype
    • +2 more
    • Biospecimen Collection
    • +2 more
    • (no location specified)
    May 13, 2023

    Astrocytoma, Grade IV, Glioblastoma, Giant Cell Glioblastoma Trial in United States (CYNK-001 systemic and Intra cavity

    Recruiting
    • Astrocytoma, Grade IV
    • +3 more
    • CYNK-001 systemic and Intra cavity administration
    • Duarte, California
    • +5 more
    Jan 20, 2023

    Glioma Trial (AB-218)

    Not yet recruiting
    • Glioma
    • (no location specified)
    Mar 29, 2022

    Isocitrate Dehydrogenase Gene Mutation Trial in Spain, United States (HMPL-306)

    Recruiting
    • Isocitrate Dehydrogenase Gene Mutation
    • Atlanta, Georgia
    • +6 more
    Feb 22, 2022

    Glioblastoma Trial in Köln, München, Münster (5-aminolevulinic acid)

    Recruiting
    • Glioblastoma
    • 5-aminolevulinic acid
    • Köln, Germany
    • +2 more
    Feb 2, 2022

    Anaplastic Astrocytoma, IDH-Wildtype, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma Trial in Houston (other,

    Recruiting
    • Anaplastic Astrocytoma, IDH-Wildtype
    • +8 more
    • Quality-of-Life Assessment
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 8, 2022

    Recurrent Glioblastoma Multiforme (GBM), Grade 3 Isocitrate Dehydrogenase (IDH) Wildtype Astrocytoma, Grade 3 or 4 Astrocytoma

    Recruiting
    • Recurrent Glioblastoma Multiforme (GBM)
    • +3 more
    • Los Angeles, California
    • +4 more
    May 5, 2022

    Biliary Carcinoma Trial in China (TQB3454 tablets, TQB3454 tablets matching )

    Not yet recruiting
    • Biliary Carcinoma
    • TQB3454 tablets
    • TQB3454 tablets matching placebo
    • Beijing, Beijing, China
    • +5 more
    Aug 4, 2023

    Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III Trial in San Antonio, Zuerich (Debio 0123,

    Not yet recruiting
    • Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
    • Astrocytoma, Grade III
    • Debio 0123
    • +2 more
    • San Antonio, Texas
    • +1 more
    Mar 9, 2023

    Leukemia, Myeloid, Acute Trial in Worldwide (AG-120, Azacitidine, AG-221)

    Active, not recruiting
    • Leukemia, Myeloid, Acute
    • Duarte, California
    • +72 more
    Aug 18, 2022

    Isocitrate Dehydrogenase Gene Mutation Trial in Spain, United States (HMPL-306)

    Recruiting
    • Isocitrate Dehydrogenase Gene Mutation
    • Santa Monica, California
    • +8 more
    Feb 22, 2022

    Glioblastoma Trial (Dose escalation of radiation dose beyond the therapeutic standard)

    Not yet recruiting
    • Glioblastoma
    • Dose escalation of radiation dose beyond the therapeutic standard
    • (no location specified)
    May 13, 2023

    Adult Gliomas, Mixed Trial in San Francisco (Hyperpolarized Carbon 13 Alpha-ketoglutarate (HP C13-aKG), Magnetic Resonance Image

    Recruiting
    • Adult Gliomas, Mixed
    • Hyperpolarized Carbon 13 Alpha-ketoglutarate (HP C13-aKG)
    • Magnetic Resonance Image (MRI)
    • San Francisco, California
      University of California, San Francisco
    May 9, 2023

    Recurrent IDH1/2 Mutated Glioma Trial in Paris (Azacitidine)

    Recruiting
    • Recurrent IDH1/2 Mutated Glioma
    • Paris, France
      Pitie Salpetriere Hospital
    Aug 29, 2022

    Clinical Development of Cancer-Specific MRS Biomarkers in

    Completed
    • Malignant Gliomas
    • +2 more
    • 3 Tesla scanning
    • Dallas, Texas
      UT Southwestern Medical Center
    Jan 19, 2022

    Cholangiocarcinoma Trial in Boston (Dasatinib)

    Completed
    Has Results
    • Cholangiocarcinoma
    • Boston, Massachusetts
    • +1 more
    Jul 20, 2020